Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Source filing unavailable
Q1 2016 · —
Revenue$7.79B$7.79B+2.6% vs Q1 2015 Net Income$3.57B$3.57B−17.7% vs Q1 2015 EPS Diluted$2.53$2.53−8.3% vs Q1 2015 Gross Profit$6,488,000,000−0.5% Operating Income$4,651,000,000−13.4% Operating Cash Flow$4,130,000,000
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
−27.6%
Free Cash Flowderived$3,953,000,000−29.1% Margins · derivedGross margin83.2%−2.7 pt vs Q1 2015
Operating margin59.7%−11.1 pt vs Q1 2015
Net margin45.8%−11.3 pt vs Q1 2015